Augmenix Lands $10,800,000 Series D Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    204 2nd Avenue Lower Level Waltham, MA 02451 USA
  • Company Description
    Augmenix, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix, Inc.’s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    These funds are anticipated to see Augmenix through to SpaceOAR System approval and US market launch, with commercialization activities expected to commence in earnest in 2015.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy